Hana Hassanin | Professor in Translational and Experimental Medicine and Medical Director of Surrey CRF
University of Surrey
Hana Hassanin is a distinguished Professor in Translational and Experimental Medicine at the University of Surrey, where she also serves as the Medical Director of the Surrey Clinical Research Facility (CRF) and Founding Director of NIHR Royal Surrey CRF. With a strong background in both academia and clinical practice, Hana is a leading expert in the field of precision medicine and healthcare innovation.
Throughout her career, Hana has been at the forefront of cutting-edge research in translational and experimental medicine, focusing on bridging the gap between basic science discoveries and clinical applications. Her work has been instrumental in advancing our understanding of disease mechanisms and developing novel therapeutic approaches for a wide range of medical conditions.
As the Medical Director of the Surrey CRF, Hana plays a pivotal role in overseeing clinical research activities and ensuring the highest standards of patient care and safety. Under her leadership, the CRF has become a hub for interdisciplinary collaboration, bringing together researchers, clinicians, and industry partners to drive innovation in healthcare.
Hana is a sought-after speaker and thought leader in the field of precision medicine, regularly sharing her expertise at national and international conferences. Her passion for leveraging data and AI to revolutionize healthcare delivery has earned her recognition as a pioneer in the field.
At BioTechX 2026, Hana will be sharing her insights on the latest advancements in data-driven approaches to precision medicine and the transformative impact of AI on healthcare. Attendees can expect to gain valuable knowledge and inspiration from her expertise in driving innovation and improving patient outcomes in the pharmaceutical and healthcare sectors.
Appearances:
BioTechX EU Day 1 @ 17:25
Improving patient care
BioTechX EU Day 2 @ 15:30
An Investigator’s Perspective on Practical Impact Beyond the Hype
Artificial intelligence is rapidly entering clinical trial design and execution, yet its value depends on how well it addresses the real-world challenges faced by investigators, sites, sponsors, and patients. This presentation explores AI in clinical trials from the investigator’s perspective, focusing not on technical algorithms but on practical clinical and operational impact.
The session will examine where AI can meaningfully support trial feasibility, patient identification, eligibility screening, recruitment, retention, risk-based monitoring, endpoint assessment, data quality, and safety oversight. It will also distinguish realistic current applications from hype, while addressing key limitations including bias, poor data quality, lack of transparency, regulatory expectations, and the risk of over-automation.
Attendees will leave with a clear framework for evaluating AI-enabled trial solutions, collaborating effectively with sponsors and technology partners, and adopting AI in ways that improve efficiency while preserving patient safety, data integrity, scientific credibility, and investigator judgment
Get involved at BioTechX Europe
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events